Amgen's obesity drug MariTide starts Phase 3, new program in Phase 1
While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play into Phase 3 studies. Amgen has emerged with one of the leading efforts in ...
While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play into Phase 3 studies.
Amgen has emerged with one of the leading efforts in ...
